FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2076394736> ?p ?o ?g. }

• W2076394736 endingPage "1148" @default.
• W2076394736 startingPage "1148" @default.
• W2076394736 abstract "Sir: We thank Dr Mion and his colleagues for their interest in our study [1], and we appreciate that this important topic is such a matter of discussion and concern. Addressing the content of Dr Mion’s letter, however, is made difficult by an unclear meaning of the word ‘‘evidence’’. First, Mion et al. argue that our study ‘‘solely proves a link between hyperoncotic albumin and probability of renal replacement therapy’’. This is strange since our results indicate that ‘‘after adjustment on potential confounding factors and on propensity score for the use of hyperoncotic colloids, the use of artificial hyperoncotic colloids [OR: 2.48 (1.24– 4.97)] and hyperoncotic albumin [OR: 5.99 (2.75–13.08)] was significantly associated with occurrence of renal event.’’ This is not an opinion but a result. We therefore concluded, carefully selecting our wording that ‘‘this suggests that harmful effects on renal function and outcome of hyperoncotic colloids may exist.’’ We believe this conclusion is cautious and data-driven. Other authors have written much stronger statements. The Cochrane collaborative group, which is usually considered to base their analyses on ‘‘evidence’’, indicated in 2007 [2], before the VISEP study [3], that ‘‘There is no evidence from randomized controlled trials (RCTs) that resuscitation with colloids reduces the risk of death, compared to resuscitation with crystalloids, in patients with trauma, burns or following surgery. As colloids are not associated with an improvement in survival, and as they are more expensive than crystalloids, it is hard to see how their continued use in these patients can be justified outside the context of RCTs.’’ A Canadian group [4], also supposed to work based on ‘‘evidence’’ recently concluded from their meta-analysis that the use of hydroxyethylstarches was significantly associated with renal replacement therapy and cautioned against the routine use of these compounds. The association between hydroxyethylstarches and renal dysfunction was also shown in another meta-analysis. The problem of the measured oncotic pressure is complex because the molecular properties of the same compound can markedly differ in vitro and in vivo. When one compound has plasma expanding effect larger the infused volume this indicates that the in vivo molecular weight has an hyperoncotic effect. This is why the hydroxyethylstarches are classified as hyperoncontic compounds, and this is also what is expected by clinicians. Because of the renal risk and other concerns, and because we could not find in the literature a single study showing a clinical ‘‘evidence’’ that colloids were beneficial for the survival of critically ill patients, we have stopped using colloids in our clinical practice. The largest study ever performed on this topic [5] (the SAFE study enrolled close to 7,000 patients) has shown that using solely crystalloids is perfectly safe. As clinicians, we would be highly interested to have a safe (and possibly inexpensive) molecule for efficient fluid loading that results in improved patient’s survival (and not only endothelial function) and welcome the development of well conducted and monitored RCTs for testing new compounds. Today, however, the problem is the complete lack of ‘‘evidence’’ in favour of any indication for using colloids. But again, the problem may be on the meaning of the word ‘‘evidence’’." @default.
• W2076394736 created "2016-06-24" @default.
• W2076394736 creator A5054873949 @default.
• W2076394736 creator A5062306514 @default.
• W2076394736 date "2009-02-17" @default.
• W2076394736 modified "2023-09-30" @default.
• W2076394736 title "Reply to Mion" @default.
• W2076394736 cites W2131316093 @default.
• W2076394736 cites W2143432233 @default.
• W2076394736 cites W2148706741 @default.
• W2076394736 cites W4248593864 @default.
• W2076394736 doi "https://doi.org/10.1007/s00134-009-1442-3" @default.
• W2076394736 hasPublicationYear "2009" @default.
• W2076394736 type Work @default.
• W2076394736 sameAs 2076394736 @default.
• W2076394736 citedByCount "0" @default.
• W2076394736 crossrefType "journal-article" @default.
• W2076394736 hasAuthorship W2076394736A5054873949 @default.
• W2076394736 hasAuthorship W2076394736A5062306514 @default.
• W2076394736 hasBestOaLocation W20763947361 @default.
• W2076394736 hasConcept C177713679 @default.
• W2076394736 hasConcept C2779526319 @default.
• W2076394736 hasConcept C2991975920 @default.
• W2076394736 hasConcept C42219234 @default.
• W2076394736 hasConcept C71924100 @default.
• W2076394736 hasConceptScore W2076394736C177713679 @default.
• W2076394736 hasConceptScore W2076394736C2779526319 @default.
• W2076394736 hasConceptScore W2076394736C2991975920 @default.
• W2076394736 hasConceptScore W2076394736C42219234 @default.
• W2076394736 hasConceptScore W2076394736C71924100 @default.
• W2076394736 hasIssue "6" @default.
• W2076394736 hasLocation W20763947361 @default.
• W2076394736 hasOpenAccess W2076394736 @default.
• W2076394736 hasPrimaryLocation W20763947361 @default.
• W2076394736 hasRelatedWork W1979404825 @default.
• W2076394736 hasRelatedWork W2013403198 @default.
• W2076394736 hasRelatedWork W2063036856 @default.
• W2076394736 hasRelatedWork W2255877608 @default.
• W2076394736 hasRelatedWork W2462769551 @default.
• W2076394736 hasRelatedWork W2923463259 @default.
• W2076394736 hasRelatedWork W2927671423 @default.
• W2076394736 hasRelatedWork W2967343934 @default.
• W2076394736 hasRelatedWork W3132436955 @default.
• W2076394736 hasRelatedWork W3212096689 @default.
• W2076394736 hasVolume "35" @default.
• W2076394736 isParatext "false" @default.
• W2076394736 isRetracted "false" @default.
• W2076394736 magId "2076394736" @default.
• W2076394736 workType "article" @default.